Outcome of Board Meeting

SUVEN® Life Sciences CSD/BM/SE/2026-27 Date: 6th August, 2026 To To Department of Corporate Services Listing Department BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 530239 Scrip Symbol: SUVEN Dear Sir/Madam, Sub: Outcome of Board Meeting Pursuant to the provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that the Board of Directors of the Company, at its meeting held today i.e. August 6, 2026, has considered and approved Un-Audited Financial Results (Standalone and Consolidated) along with review reports of the Statutory Auditors for the quarter ended 30th June, 2026. Enclosed herewith the following documents:- 1. The Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026 enclosed as Annexure 1 2. Limited Review Reports of Statutory Auditors of the Company enclosed as Annexure 2 3. News Release of the Company enclosed as Annexure 3 Update on patents are available at: https://www.suven.com/Patentupdates.aspx The Board Meeting commenced at 11:30 AM (IST) and concluded at 12:30 PM (IST). This is for your information and records. Thanking you. Yours faithfully, For Suven Life Sciences Limited K.Sangeetha Laxmi Company Secretary and Compliance officer Suven Life Sciences Limited Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com SUVEN LIFE SCIENCES LIMITED Registered Office: 8-2-334, SOE Serene Chambers, 6th Floor, Road No. 5, Avenue 7, Banjara Hills, 500034, Telangana, India Tel: 91 40 2354 1142/ 1152 Email: investorservices@suvcn.com Website: www.suven.com CIN: L24 l I 0TG I 989PLC009713 STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 Rs. In Lakhs STANDALONE For the Year For the Quarter Ended ended SI.No. e PARTICULARS 30/06/2026 31/03/2026 30/06/2025 31/03/2026 Un-Audited Refer note. 7 Un-Audited Audited l Income Revenue from operations 356.58 152.01 186.67 711.47 Other Income. 752.36 677.78 58.90 1,391.05 Total income 1,108.94 829.79 245.57 2,102.52 2 Expenses a) Cost of materials consumed - - - - b) Changes in inventories of finished goods, work-in- - - - - progress and stock-in-trade c) Employee benefits expense 728.18 582.89 597.56 2,414.94 d) Finance costs 47.61 15.78 - 15.78 e) Depreciation and amortisation expenses 215.51 158.25 136.84 561.35 f) R & D Expenses 1,275.60 810.19 518.77 2,797.24 g) Other Expenses 453.95 379.41 470.27 1,799.49 Total expenses 2,720.85 1,946.52 1,723.44 7,588.80 3 t'rofit before exceptional items & Tax (l-2) (1,61 i.91) (1,116.73) (1,477.87) (5,486.28) 4 Exceptional Items - - - - 5 Profit/(Loss) before Tax (3-4) (l,61 L91) (1,116.73) (1,477.87) (5,486.28) 6 Tax Expenses a) Current tax - - - - b) Deferred tax - - - - c) Tax of earlier years - - - - 7 Net Profit/ (Loss) for the period/year(5-6) (l,61 L91) (1,116.73) (1,477.87) (5,486.28) 8 Other Comprehensive Income 8.a (i) Items that will not be reclassified to profit or loss (5.55) (22.45) (LS0) (22.19) (ii) Income tax relating to items that will not be reclassified to profit or loss - - - - 8.b (i) Items that will be reclassified to profit or loss - - - - (ii) Income tax relating to items that will be reclassified to profit or loss - - - - Total other Comprehensive Income (5.55) (22.45) (LS0) (22.19) 9 Total Comprehensive Income for the period (7+8) (1,617.46) (1,139.18) (1,479.37) (5,508.47) 10 Paid-up equity share capital 2,639.93 2,637.20 2,180.74 2,637.20 Face Value of the Share Re.LOO Re.LOO Re.LOO Re.LOO 11 Other Equity - - - 147,699.51 Earning Per Share (EPS) (Face value of Rs.1/-each) a) Basic (0.61) (0.50) (0.68) (2.41) b) Diluted (0.61) (0.50) (0.68) (2.41) (not annualised) (not annualised) (not annualised) ( annualised) Page 1 Rs. In Lakhs CON SO LIDA TED For the Year For the Quarter Ended ended SI. No. PARTICULARS 30/06/2026 31/03/2026 30/06/2025 31/03/2026 Un-Audited Refer note. 7 Un-Audited Audited 1 Income Revenue from operations 356.58 152.01 186.67 711.47 Other Income 752.36 677.78 59.98 1,393.01 Total income 1,108.94 829.79 246.65 2,104.48 2 Expenses a) Cost of mate!·ials consumed - ,· - - - b) Changes in inventories of finished goods, work-in- ' •· progress and stock-in-trade - - - - c) Employee benefits expense 728.18 582.89 597.56 2,414.94 d) Finance costs 47.61 15.78 - 15.78 e) Depreciation and amortisation expense 215.51 158.25 136.84 561.35 f) R & D Expenses 12,383.10 4,233.12 4,148.84 24,818.81 g) Other Expenses 495.57 399.30 515.10 1,928.01 Total expenses 13,869.97 5,389.34 5,398.34 29,738.89 3 Profit before exceptional items, Tax (1-2) (12,76L03) (4,559.55) (5,15L69) (27,634.41) 4 Exceptional Items - - - - 5 Profit/(Loss) before Tax (3-4) (12,76L03) (4,559.55) (5,15L69) (27,634.41) ~ - Tax Expenses a) Current tax - - - - b) Deferred tax - - - - c) Tax of eariier years - - - - 7 Net Profit/ (Loss) for the period/year(S-6) (12,76L03) (4,559.55) (5,15L69) (27,634.41) 8 Other Comprehensive Income 8.a (i) Items that will not be reclassified to profit or loss (5.55) (22.45) (1.50) (22.19) (ii) Income tax relating to items that will not be reclassified to profit or loss - - - - 8.b (i) Items that will be reclassified to profit or loss 1.95 (24.21) (3.62) (96.20) (ii) Income tax relating to items that will be reclassified to profit or loss - - - - Total other Comprehensive Income (3.60) (46.66) (5.12) (118.39) 9 Total Comprehensive Income for the period (7+ 8) (12,764.63) (4,606.21) (5,156.81) (27,752.80) 10 Paid-up equity share capital 2,639.93 2,637.20 2,180.74 2,637.20 Face Value of the Share Re.LOO Re.LOO Re.LOO Re.LOO 11 Other Equity - - - 56,502.76 Earning Per Share (EPS) (Face value of Rs.I/- each) a) Basic (4.84) (2.02) (2.36) (12.13) b) Diluted (4.84) (2.02) (2.36) (12.13) (not annualised) (not annualised) (nol annualised) (annualised) Page 2 NOTES:- 1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 06, 2026. The financial results for the quarter ended June 30, 2026 has been reviewed by our statutory auditors and issued unmodified reports thereon. 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3) Jhe consolidated financial results include the results of the wholly Ow!1ed Subsidiary, Suven Neurosciences, Inc. 4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS I 08 (Operating Segment) is not presented. 5.1) The Company implemented SLSL Employee Stock Option Scheme 2020 ("ESOP") for eligible employees, 1,33,200 stock options were.granted on May 13,2026 by the Nomination & Remuneration Committee. 5.2) ESOP: for the quarter ended June 30, 2026, the Company has recognized an employee benefit expense (EBP) of Rs. 145.54 lakhs in accordance with Ind AS I 02 - Share-based Payment. 5.3) During the quarter ended June 30, 2026, the Company has allotted 2, 71,970 equity shares of Rs. I each, pursuant to the exercise of stock options by the employees of the company under Employee Stock Options Scheme 2020. 6) Preferential Issue: The Board of Directors· of the Company has approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees in its meeting held on 13th May, 2025, in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulatio [Showing first 8,000 characters — download PDF for full document]